All In Biotech

Drug Trial Radar · NCT06498479

ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

ARTEMIS-008:A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 461 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

461

Actual

Start

Jul 4, 2024

Primary completion

Aug 20, 2026

Study completion Aug 20, 2026

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Jul 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).

Conditions

  • Small Cell Lung Cancer

Interventions

  • HS-20093Drug

    HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.

  • TopotecanDrug

    Topotecan will be administered per drug label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: From the date of randomization to the date of death due to any cause; Up to approximately 4.5 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliate Hospital of GUANGZHOU Medical University

    Guangzhou, China

  • Tongji Hospital

    Wuhan, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.